Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope

被引:64
作者
Yang, ZY [1 ]
Chakrabarti, BK [1 ]
Xu, L [1 ]
Welcher, B [1 ]
Kong, WP [1 ]
Leung, K [1 ]
Panet, A [1 ]
Mascola, JR [1 ]
Nabel, GJ [1 ]
机构
[1] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1128/JVI.78.8.4029-4036.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Although the B clade of human immunodeficiency virus type 1 (HIV-1) envelopes (Env) includes five highly variable regions, each of these domains contains a subset of sequences that remain conserved. The V3 loop has been much studied for its ability to elicit neutralizing antibodies, which are often restricted to a limited number of closely related strains, likely because a large number of antigenic structures are generated from the diverse amino acid sequences in this region. Despite these strain-specific determinants, subregions of V3 are highly conserved, and the effects of different portions of the V3 loop on Env tropism and immunogenicity have not been well delineated. For this report, selective deletions in V3 were introduced by shortening of the stem of the V3 loop. These mutations were explored in combination with deletions of selected V regions. Progressive shortening of the stem of V3 abolished the immunogenicity as well as the functional activity of HIV Env; however, two small deletions on both arms of the V3 stem altered the tropism of the dualtropic 89.6P viral strain so that it infected only CXCR4(+) cells. When this smaller deletion was combined with removal of the V1 and V2 loops and used as an immunogen in guinea pigs, the antisera were able to neutralize multiple independent clade B isolates with a higher potency. These findings suggest that highly conserved subregions within V3 may be relevant targets for eliciting neutralizing antibody responses, affecting HIV tropism, and increasing the immunogenicity of AIDS vaccines.
引用
收藏
页码:4029 / 4036
页数:8
相关论文
共 25 条
  • [1] Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro
    Aoki, K
    Barker, C
    Danthinne, X
    Imperiale, MJ
    Nabel, GJ
    [J]. MOLECULAR MEDICINE, 1999, 5 (04) : 224 - 231
  • [2] Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages)
    Briggs, DR
    Tuffle, DL
    Sleasman, JW
    Goodenow, MM
    [J]. AIDS, 2000, 14 (18) : 2937 - 2939
  • [3] Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
    Bures, R
    Gaitan, A
    Zhu, TF
    Graziosi, C
    McGrath, KM
    Tartaglia, J
    Caudrelier, P
    EL Habib, R
    Klein, M
    Lazzarin, A
    Stablein, DM
    Deers, M
    Corey, L
    Greenberg, ML
    Schwartz, DH
    Montefiori, DC
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) : 2019 - 2035
  • [4] Burns D P, 1994, Curr Top Microbiol Immunol, V188, P185
  • [5] Antibodies, viruses and vaccines
    Burton, DR
    [J]. NATURE REVIEWS IMMUNOLOGY, 2002, 2 (09) : 706 - 713
  • [6] Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein
    Cao, J
    Sullivan, N
    Desjardin, E
    Parolin, C
    Robinson, J
    Wyatt, R
    Sodroski, J
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (12) : 9808 - 9812
  • [7] Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization
    Chakrabarti, BK
    Kong, W
    Wu, B
    Yang, ZY
    Friborg, J
    Ling, X
    King, SR
    Montefiori, DC
    Nabel, GJ
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (11) : 5357 - 5368
  • [8] Gorny MK, 1997, J IMMUNOL, V159, P5114
  • [9] Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades
    Gorny, MK
    Williams, C
    Volsky, B
    Revesz, K
    Cohen, S
    Polonis, VR
    Honnen, WJ
    Kayman, SC
    Krachmarov, C
    Pinter, A
    Zolla-Pazner, S
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (18) : 9035 - 9045
  • [10] Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction
    Guillon, C
    Schutten, M
    Boers, PHM
    Gruters, RA
    Osterhaus, ADME
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (06) : 2827 - 2834